On December 8, Roche Diagnostics China (hereinafter referred to as "Roche") and SHAPHAR announced the opening of a new round of strategic cooperation. Mr. Yao Guoliang, general manager of Roche Diagnostics China, Chen Xianglin, vice president of Roche Diagnostics China, Chen Jintian, vice president of Roche Diagnostics China, and Wang Xin, senior financial manager of health care department of Roche Diagnostics China; Li Yongzhong, executive director, vice president, general manager of Shanghai Pharmaceutical Holding and chairman of SHAPHAR, Ren Gang, deputy general manager of Shanghai Pharmaceutical Holding, Dong Linqiong, deputy general manager and chief financial officer of Shanghai Pharmaceutical Holding, Ai Li, deputy general manager of Shanghai Pharmaceutical Holding and general manager of SHAPHAR, attended and witnessed the signing.

The purpose of this cooperation is to rely on the perfect medical device logistics and storage resources of SHAPHAR, integrate the end-to-end supply chain demand of Roche, jointly improve the supply chain service capacity, and actively explore and create a new business form of smart supply chain.

Mr. Yao Guoliang, general manager of Roche, pointed out: "Over the past 20 years since entering China, Roche has always adhered to the concept of" acting first to the needs of patients ", constantly improving the accessibility of our high-quality innovative diagnostic solutions, so that Roche` s innovative products can benefit more patients. Through actively working together with high-quality local partners such as SHAPHAR, we hope to further accelerate the construction of China' s local medical ecosystem and jointly promote the development of Move towards the realization of the vision of HEALTHY CHINA 2030. "

As a revolutionary technology, new generation of sequencing (NGS) has been widely used in many fields such as early screening of tumors, accompanying diagnosis, infectious diseases and so on after years of rapid development. However, at the same time, NGS laboratory is still facing challenges such as cumbersome operation process, detection efficiency and quality management. Realizing laboratory automation and intelligent management is the inevitable trend of the future development of sequencing industry.

NGS technology enables high-throughput and high-depth detection of the genome in a short time, making personalized precision medicine possible. However, the complex experimental process is still the key threshold for non central laboratories to detect NGS. Among them, the experimental operation steps for the preparation of NGS library are particularly cumbersome and lengthy. Even the most advanced laboratories are subject to the number of steps still being performed manually, which makes the experimenters often work for a long time in front of the test bench. The whole process is labor-intensive, time-consuming and error prone, resulting in the waste of samples and reagents.

Combined with the library reagents of Roche in various application fields such as whole gene sequencing, whole exon sequencing, tumor targeted sequencing, methylation sequencing and metagenome sequencing, avinio edge system upgrades high-throughput sequencing to an automatic pipeline, helps the laboratory break many technical and management bottlenecks and optimize R & D workflow and efficiency, Significantly expand the scope of use of NGS, greatly improve the accessibility of precision medical research, and promote the acceleration of more research projects.